Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches

BJU International

Volumn 110, Issue 6B, 2012, Pages

  Koga, Fumitaka ^a   Fujii, Yasuhisa ^a   Masuda, Hitoshi ^a   Numao, Noboru ^a   Yokoyama, Minato ^a   Ishioka, Jun Ichiro ^a   Saito, Kazutaka ^a   Kawakami, Satoru ^a   Kihara, Kazunori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

carcinoma invading bladder muscle; chemoradiotherapy; partial cystectomy; radical cystectomy; risk factor; survival

Indexed keywords

CISPLATIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CYSTECTOMY; FEMALE; FOLLOW UP; HAZARD RATIO; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RADIATION DOSE; RISK ASSESSMENT; RISK FACTOR; SURGICAL APPROACH; TRANSURETHRAL RESECTION; TREATMENT RESPONSE;

AGED; CHEMORADIOTHERAPY; CYSTECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SMOOTH; NEOPLASM INVASIVENESS; NEOPLASM STAGING; REMISSION INDUCTION; RISK ASSESSMENT; URINARY BLADDER NEOPLASMS;

EID: 84865499773     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10874.x     Document Type: Article

References (28)

1. Gilbert SM, Wood DP, Dunn RL, et al,. Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI). Cancer 2007; 109: 1756-62 (Pubitemid 46668537)
2. Herr HW,. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 2001; 19: 89-93 (Pubitemid 32063483)
3. Herr HW, Bajorin DF, Scher HI,. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 1998; 16: 1298-301 (Pubitemid 28175743)
4. Shelley MD, Barber J, Wilt T, Mason MD,. Surgery versus radiotherapy for muscle invasive bladder cancer. Cochrane Database Syst Rev 2002; (1): CD002079
5. Hagan MP, Winter KA, Kaufman DS, et al,. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 2003; 57: 665-72 (Pubitemid 37194292)
6. Rodel C, Grabenbauer GG, Kuhn R, et al,. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002; 20: 3061-71 (Pubitemid 34791095)
7. Shipley WU, Kaufman DS, Zehr E, et al,. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002; 60: 62-7; discussion 7-8 (Pubitemid 34722947)
8. Shipley WU, Prout GR Jr, Einstein AB, et al,. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 1987; 258: 931-5 (Pubitemid 17125826)
9. Tester W, Porter A, Asbell S, et al,. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 1993; 25: 783-90 (Pubitemid 23123381)
10. Weiss C, Engehausen DG, Krause FS, et al,. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 2007; 68: 1072-80 (Pubitemid 47048579)
11. Dalbagni G, Genega E, Hashibe M, et al,. Cystectomy for bladder cancer: a contemporary series. J Urol 2001; 165: 1111-6 (Pubitemid 32210214)
12. Stein JP, Lieskovsky G, Cote R, et al,. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666-75 (Pubitemid 32120143)
13. Zietman AL, Sacco D, Skowronski U, et al,. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 2003; 170: 1772-6 (Pubitemid 37254925)
14. Coppin CM, Gospodarowicz MK, James K, et al,. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14: 2901-7 (Pubitemid 26371447)
15. Sauer R, Birkenhake S, Kuhn R, Wittekind C, Schrott KM, Martus P,. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys 1998; 40: 121-7
16. Koga F, Kihara K, Fujii Y, et al,. Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low-dose chemo-radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a single-institutional retrospective comparative study. BJU Int 2009; 104: 189-94
17. Koga F, Kihara K, Yoshida S, et al,. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients. BJU Int 2011; DOI:10.1111/j.1464-410X. 2011.10425.x. [Epub ahead of print]
18. Koga F, Yoshida S, Kawakami S, et al,. Low-dose chemoradiotherapy followed by partial or radical cystectomy against muscle-invasive bladder cancer: an intent-to-treat survival analysis. Urology 2008; 72: 384-8
19. Yoshida S, Koga F, Kawakami S, et al,. Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer. Urology 2010; 75: 387-91
20. Kihara K, Kawakami S, Fujii Y, Masuda H, Koga F,. Gasless single-port access endoscopic surgery in urology: minimum incision endoscopic surgery, MIES. Int J Urol 2009; 16: 791-800
21. Cheng L, Montironi R, Davidson DD, Lopez-Beltran A,. Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol 2009; 22 (Suppl. 2): S70-95
22. Sobin LH, Wittekind C, eds. Classification of Malignant Tumours, 6th edn. New York: Wiley-Liss, 2002
23. Cohen SM, Goel A, Phillips J, Ennis RD, Grossbard ML,. The role of perioperative chemotherapy in the treatment of urothelial cancer. Oncologist 2006; 11: 630-40 (Pubitemid 43967618)
24. Paz-Ares LG, Solsona E, Esteban E, et al,. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. J Clin Oncol 2010; 28: LBA4518
25. Holzbeierlein JM, Lopez-Corona E, Bochner BH, et al,. Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol 2004; 172: 878-81 (Pubitemid 39096412)
26. Kassouf W, Swanson D, Kamat AM, et al,. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol 2006; 175: 2058-62 (Pubitemid 43668585)
27. Bryne M, Boysen M, Alfsen CG, et al,. The invasive front of carcinomas. The most important area for tumour prognosis? Anticancer Res 1998; 18: 4757-64 (Pubitemid 29042056)
28. Koga F, Kageyama Y, Kawakami S, et al,. Prognostic significance of endothelial Per-Arnt-sim domain protein 1/hypoxia-inducible factor-2alpha expression in a subset of tumor associated macrophages in invasive bladder cancer. J Urol 2004; 171: 1080-4 (Pubitemid 38327531)